When you think about everything that goes into bringing a medical device to market, packaging can sometimes feel like one of the more straightforward pieces of the process. Choose a material. Seal the device. Validate the package. Move on.
Packaging Validation: More Than Checking a Box
When you think about everything that goes into bringing a medical device to market, packaging can sometimes feel like one of the more straightforward pieces of the process. Choose a material. Seal the device. Validate the package. Move on.
In reality, there is a lot riding on that package.
For a terminally sterilized medical device, the sterile barrier system has to do two seemingly opposite things. It needs to allow the device to be effectively sterilized, while also protecting that device from microorganisms and other hazards until the moment it is opened for use.
That is why packaging validation is not simply about proving that a pouch seals properly or that a package survives shipping. It is about building a body of evidence that the packaging system can consistently protect the device throughout sterilization, handling, distribution, storage, and its claimed shelf life. And for packages that contain porous materials, one important piece of that evidence is understanding the material’s microbial barrier.
What Goes Into a Packaging Validation?
A packaging validation typically looks at several different aspects of package performance.
Depending on the device and packaging configuration, this can include seal strength, package integrity, distribution testing, aging or stability testing, and microbial barrier evaluation.
Each answers a slightly different question.
Can the seals withstand the forces they are expected to experience? Does the package remain intact after distribution? Will the sterile barrier maintain its integrity throughout the device’s shelf life? And, when porous materials are involved, how effectively does that material resist microbial penetration?
The goal is not to rely on one passing test. It is to understand how the entire packaging system performs. This is also why packaging validation should be considered earlier in the development process than it sometimes is. As our team at Canyon Labs sees regularly, packaging validation can become one of the later items addressed in a development program, even though the testing and aging timelines can make it one of the longer pieces of the process. Thinking about packaging early can help identify material, seal, integrity, and validation concerns before they become timeline problems.
Where Does Microbial Barrier Testing Fit?
ISO 11607-1 establishes requirements for packaging used with terminally sterilized medical devices. For porous materials, the standard requires the material to provide an adequate microbial barrier.
That distinction matters because porous packaging materials have a unique job. They may need to allow sterilant to enter the package during processing while helping prevent microorganisms from entering afterward.
As one of our SMEs put it during a recent Canyon Labs discussion, you have to let the “good stuff” in while keeping the “bad stuff” out.
Not every porous packaging material performs exactly the same way, either. Materials can differ considerably in their barrier properties, which makes understanding the material selected for a particular application an important part of the overall packaging strategy.
This is where ASTM F1608 comes into the picture.
A Closer Look at ASTM F1608
ASTM F1608, Standard Test Method for Microbial Ranking of Porous Packaging Materials (Exposure Chamber Method), is used to evaluate the resistance of porous packaging materials to penetration by airborne bacteria.
In simple terms, the test challenges a porous material with microorganisms under controlled conditions and measures how effectively the material acts as a barrier.
The results are expressed as a log reduction value, or LRV. A higher LRV indicates greater resistance to bacterial penetration under the conditions of the test. One important point is that F1608 is a ranking method. It helps characterize and compare the microbial barrier properties of porous materials. There is not one universal LRV that every medical device package must achieve.
That means the number itself is only part of the story.
Manufacturers need to understand what the result means for their particular material, device, packaging design, sterilization process, intended use, and associated risks.
Material Testing and Package Integrity Are Not the Same Thing
This is where packaging validation can get confusing.
ASTM F1608 evaluates the porous material, not the entire finished sterile barrier system.
A material could demonstrate strong microbial barrier properties while the finished package still has a problem. A channel in a seal, a puncture, a tear, or another package defect can create an entirely different route for contamination.
The opposite is also true. Passing package integrity testing does not independently tell you how the porous material itself performs as a microbial barrier.
That is why these tests complement one another.
Microbial barrier testing helps characterize the porous material. Seal strength and package integrity testing evaluate the assembled sterile barrier system. Distribution testing looks at how the package withstands the stresses of transportation and handling. Aging and stability testing help demonstrate that the package continues to perform throughout its claimed shelf life.
Together, they provide a much more complete picture than any one test can provide on its own.
Does Every Packaging Validation Need New F1608 Testing?
Not necessarily.
ISO 11607-1 requires manufacturers to establish microbial barrier properties for porous materials, but that does not mean every project automatically requires a brand-new F1608 study.
In some cases, existing supplier data may provide adequate evidence, particularly for established medical-grade packaging materials. The important question is whether that data is actually applicable to the material and application being validated. Manufacturers should consider factors such as the specific material grade and basis weight, manufacturer and manufacturing process, coatings or other converting operations, sterilization method, aging conditions, and the final sterile barrier application. When the existing information is applicable, it may support the material qualification strategy.
When it is missing, incomplete, or not representative, F1608 provides a standardized method for developing additional microbial barrier evidence. Changes can also trigger a closer look. For example, switching to a different packaging material or material grade may warrant additional evaluation to understand how its barrier properties compare with the previously validated material. This was another scenario specifically highlighted by the Canyon Labs team.
What About Aging?
Shelf-life validation is another area where F1608 can be misunderstood.
The packaging system needs to maintain sterile barrier integrity for its claimed shelf life, but that does not automatically mean F1608 needs to be repeated at every aging interval. The decision should be based on risk. If aging, sterilization, or another exposure could reasonably change the porous structure or microbial barrier properties of the material, additional testing may make sense. In other applications, the primary aging concerns may be related more closely to seals, bonds, or overall package construction.
The important part is being able to explain and document the rationale behind the testing strategy.
Building the Right Packaging Validation Strategy
There is no single test that can tell you everything you need to know about a sterile barrier system.
A strong packaging validation strategy brings together the right combination of material qualification, seal testing, integrity testing, distribution testing, aging, and microbial barrier evidence to demonstrate that the packaging system can do its job from sterilization through point of use.
ASTM F1608 is one piece of that larger picture.
At Canyon Labs, our teams work across packaging and microbiology to help manufacturers evaluate packaging systems as part of the broader product development and validation process. Rather than looking at F1608 as an isolated test request, we can help determine where microbial barrier testing fits alongside the other evidence needed to support a packaging validation.
Because ultimately, the question is not simply, “Do I need F1608?”
The better question is:
“Do I have the right evidence to demonstrate that my packaging system will protect my sterile device throughout its intended life?”
Answering that question early can make for a stronger validation strategy and fewer surprises when a device is getting closer to market.
About Canyon Labs
Canyon Labs provides integrated testing, validation, and regulatory consulting services for medical device manufacturers. Its capabilities span microbiology, biocompatibility, analytical chemistry, packaging validation, reusable-device reprocessing validation, and regulatory support, helping customers move from development through commercialization with coordinated scientific and compliance expertise.